Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.55 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.55 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1814610 | 0.94 | SLC6A9 (0.53) | CYP2C9CYP2C19MAPK14SLC6A9HTR2B | |
| SCHEMBL1813353 | 0.86 | SLC6A9 (0.54) | SLC6A9KCNH2 | |
| SCHEMBL1814913 | 0.85 | SLC6A9 (0.50) | SLC6A9KCNH2 | |
| SCHEMBL1811913 | 0.85 | SLC6A9 (0.54) | MAPK14SLC6A9KCNH2 | |
| SCHEMBL1813763 | 0.85 | SLC6A9 (0.51) | SLC6A9KCNH2 | |
| SCHEMBL3077440 | 0.83 | SLC6A9 (0.62) | SLC6A9KCNH2 | |
| SCHEMBL1812937 | 0.83 | SLC6A9 (0.68) | SLC6A9KCNH2 | |
| SCHEMBL1816692 | 0.81 | SLC6A9 (0.57) | SLC6A9KCNH2 | |
| SCHEMBL3082386 | 0.81 | SLC6A9 (0.59) | SLC6A9KCNH2 | |
| SCHEMBL3072470 | 0.79 | SLC6A9 (0.57) | SLC6A9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035371-B1 | SUBSTITUTED PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYT1 AND GLYT2 RECEPTOR INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-7951836-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951836-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951836-B2 | Substituted phenyl methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| US-20070299071-A1 | Substituted phenyl methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | US | disclosed |
| WO-2007147770-A2 | SUBSTITUTED PHENYL METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299071-A1 | Substituted phenyl methanone derivatives | CYP11B1, CYP11B2, MC2R | CYP2C9 169/4885CYP2C19 16/4885MAPK14 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.